Genomma Lab Internacional, S.A.B. de C.V. (LABB) Earnings Call Transcripts
Genomma Lab Internacional, S.A.B. de C.V.'s Latest Earnings Call - Q1 FY2026
In the first quarter of 2026, Genomma Lab Internacional reported net sales of MXN 4.2 billion, reflecting a decline of 4.9% year-over-year, primarily due to a challenging consumption environment in Mexico and significant foreign exchange headwinds. The company experienced a like-for-like sales decline of 3.9%, with gross margin expanding to 63.4% but EBITDA margin decreasing to 22.8%. Management signaled a cautious outlook, expecting recovery in market share and sales growth to materialize between Q2 and Q3 2026, while also indicating potential short-term pressure on margins due to increased investments in market share defense.
Reported metrics
| Metric | Value |
|---|---|
| Net Sales | MXN 4.2 billion (miss) |
| Like-for-Like Sales | -3.9% (miss) |
| Gross Margin | 63.4% (beat) |
| EBITDA Margin | 22.8% (miss) |
| Net Income | MXN 495 million (inline) |
| Free Cash Flow | MXN 2 billion (miss) |
Guidance from management
Management expects recovery in market share and sales growth between Q2 and Q3 2026, with EBITDA margins pressured in the short term due to increased investments in market share defense.
What analysts pressed on
Analysts expressed concerns about the slower-than-expected recovery in Mexico and the potential for continued margin pressure. There were questions regarding the sustainability of growth in Latin America and how the company plans to address the competitive landscape in Mexico.
Main topics on the call
- Market Share Recovery Initiatives — Genomma is seeing early signs of market share recovery in Mexico, with management stating, "we can see sequential improvements versus the full year 2025 across categories." The company is implementing targeted interventi...
- Challenging Consumption Environment — The company highlighted a tough consumption environment in Mexico, with Marco Sparvieri noting, "the categories as a macro level are suffering beyond what I was expecting." This has led to a decline in sellout, particula...
- Latin America Growth — Despite challenges in Mexico, Latin America is showing strong performance with a 5.3% like-for-like sales growth. Management emphasized, "our core business outside Mexico and the U.S. is growing," particularly in Argenti...
- Margin Pressure and Investments — Management anticipates short-term EBITDA margin pressure due to increased investments in growth initiatives, stating, "this will put a little bit of pressure in the margin at least during second quarter and the third qua...
Read the full Genomma Lab Internacional, S.A.B. de C.V. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional, S.A.B. de C.V. (LABB) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on BMV and is based in MX. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 27 calls on record spanning February 27, 2020 to July 23, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 27 Genomma Lab Internacional, S.A.B. de C.V. earnings call transcripts on record, spanning February 27, 2020 to July 23, 2026. Based on this history, Genomma Lab Internacional, S.A.B. de C.V. reports quarterly. The most recent call on file is dated July 23, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- LABB
- Exchange
- BMV
- Country
- MX
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 27
- First call
- February 27, 2020
- Most recent
- July 23, 2026
- Reporting cadence
- quarterly